Silence Therapeutics PLC (SLN) Peer Comparison

$19.78

$0.00 (0.00%)

As on 27-Oct-2026 16:27EDT

Market cap

$1,224 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

2.6

Div. Yield

0 %

Edit

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Market cap ($ Mln)	1,224	2,698	2,496	1,595	793
Revenue ($ Mln)	1	450	549	121	366
Net Profit ($ Mln)	-59.95	-188.21	17.88	-57.76	9.27
Net Margin (%)	-9,759.23	-41.86	3.26	-47.60	2.53
RoE (%)	-118.98	-28.46	1.43	-9.91	3.39
Price to Earnings	--	--	143.60	--	86.15
Price-To-Book	2.61	4.56	2.25	3.65	2.95

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Operating Revenue	0.61	449.61	549.12	120.79	366.45
Cost of Revenue	0.30	195.71	548.01	19.21	49.36
Gross Profit	0.34	269.08	212.72	12.07	330.63
Operating Expenses	67.15	517.90	35.89	154.86	304.74
Operating Profit (EBIT)	-66.84	-264.00	-34.78	-118.11	12.35
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-59.95	-190.72	20.08	-57.14	15.84
Provision for Tax	0.00	-2.51	1.66	0.62	6.57
Profit after Tax (Net Income)	-59.95	-188.21	17.88	-57.50	9.27
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Shareholder's Funds	38.47	607.04	1,260.78	568.41	270.49
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	55.23	39.17	186.25	123.56	104.25
Current Liabilities	12.71	428.58	275.21	81.11	93.25
Total Liabilities	131.44	1,172.38	1,753.10	784.68	499.81

Assets ($ Mln)

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Non-Current Assets	12.13	160.76	183.02	575.59	187.30
Current Assets	94.28	914.04	1,553.41	197.49	280.69
Total Assets	131.44	1,172.38	1,753.10	784.68	499.81
Total Debt*	0.11	254.58	94.51	127.33	113.30
Net Current Assets	81.57	485.45	0.00	116.38	187.44

Cashflow ($ Mln)

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Cash From Operating Activities	-62.27	-150.79	-64.66	-49.95	54.71
Cash Flow from Investing Activities	-47.99	307.87	-29.41	0.12	26.25
Cash from Financing Activities	0.02	72.35	7.84	147.34	1.50
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
ROCE (%)	-104.49	-18.15	41.92	-15.42	0.77
ROE (%)	-118.98	-28.46	1.43	-10.06	3.39
ROA (%)	-40.08	-12.55	0.66	-6.60	1.69
EBIT Margin (%)	-9,892.63	-41.09	-6.33	-42.43	8.34
Net Margin (%)	-9,759.23	-41.86	3.26	-47.60	2.53
Cash Profit Margin (%)	-0.02	0.00	--	--	0.00

Growth Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Revenue Growth (%)	-97.63	5.10	-8.81	602.33	-99.61
EBIT Growth (%)	26.29	11.36	-76.55	17.93	523.06
Net Profit Growth (%)	31.30	11.44	-96.17	43.71	-99.68
EPS Growth (%)	31.24	-1.87	-96.17	47.43	-96.78
Book Value Growth (%)	-59.14	-25.05	2.54	-6.65	7.71

Valuation Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Price / Earnings	-1.08	-11.11	5.08	-13.58	469.58
Price / Book Value	1.54	2.73	1.88	2.32	4.83
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.12	-9.39	-25.56	-18.38	36.65
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debt to Equity	0.00	0.00	0.00	0.19	0.34
Short term debt to equity ratio	0.00	0.40	0.02	0.02	0.03
Current Ratio	7.42	2.13	5.64	2.43	3.01
Quick Ratio	7.42	1.92	5.50	2.09	2.31
Interest Coverage	--	-30.87	-19.05	-4.06	2.08

Operating Efficiency Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debtors to sales (%)	1,512.64	16.23	21.41	47.25	15.55
Asset Turnover	0.00	0.30	0.20	0.14	0.67
Receivable days	8,295.02	77.60	104.79	380.35	51.78
Inventory Days	--	109.55	49.57	791.94	492.02
Payable days	6,253.37	231.78	47.68	931.00	466.91
Cash Conversion Cycle	--	-44.63	106.67	241.30	76.89

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly